FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031626646> ?p ?o ?g. }

• W2031626646 endingPage "B92" @default.
• W2031626646 startingPage "B92" @default.
• W2031626646 abstract "Abstract Introduction: Despite the widespread use of prostate specific antigen screening for early detection, prostate cancer remains the second leading cause of cancer related death among men in the US. Metastatic, hormone refractory prostate cancer (HRPCa) is the end stage, lethal form of the disease. Defining the molecular mechanisms underlying the transition of an androgen responsive prostate cancer represents an important clinical problem. Currently, no effective therapies exist for end stage, hormone refractory disease. In this study, we investigated the differentially expressed genes in primary prostate tumor vs. hormone refractory prostate tumor in order to identify potentially important therapeutic targets. Methods: Formalin fixed paraffin embedded tumor samples from 14 cases (8 primary, chemotherapy-naïve and 6 locally recurrent, hormonal therapy-refractory carcinomas) were analyzed for the whole genome RNA (29,285 transcripts) microarray analysis using Illumina cDNA-mediated annealing, selection, extension and ligation (DASL) process with the HumanHT-12 v4 beadChip (Illumina Inc., San Diego, CA). Additionally, a select number of chemotherapy-predictive (theranostic) biomarkers were analyzed using immunohistochemical methods. Results: Transcriptome analysis identified 299 genes highly differentially expressed between the primary and recurrent groups (p-value &lt; 0.01, Student's t-test). Using these 299 genes, we performed two dimensional hierarchical clustering and were able to discover 8 clusters corresponding to 5 general patterns: Pattern 1-underexpressed in both groups but more so in recurrent than primary (2 clusters with 28 and 22 genes respectively); Pattern 2-slightly overexpressed in primary and underexpressed or no change in recurrent (1 cluster with 65 genes); Pattern 3-slightly under expressed/ no change in primary and overexpressed in recurrent (1 cluster, 12 genes); Pattern 4-overexpressed in primary and no change in recurrent (1 cluster, 25 genes); Pattern 5 - overexpressed in both groups but more so in recurrent than primary (3 clusters with 58, 32, and 57 genes in each cluster). Individual gene analysis revealed upregulation of androgen receptor (AR) mRNA in recurrent HRPCa. This was, however, accompanied by a down regulation of regulator of G-protein signaling 2 (RGS2) and ras responsive element binding protein 1 (RREB1). Consistent down regulation of excision repair cross-complementing group 1 (ERCC1) and thymidylate synthase (TS) proteins were also observed in HRPCa. Conclusion: Up-regulation of AR in HRPCa is associated with down regulation of androgen receptor signaling co-regulators (RGS2 and RREB1), providing a mechanism of androgen-independent activation of AR in HRPCa. Platinum based drugs may have potential benefit in treating of HRPCa due to the down regulation of nucleotide excision repair protein ERCC1, while fluoropyrimidines are potentially beneficial due to the lack of TS protein expression in HRPCa. The heat map derived signature readily distinguishes between prostate cancer specimens from men who were treatment naïve vs. hormone refractory cancers with 5 different expression patterns. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B92." @default.
• W2031626646 created "2016-06-24" @default.
• W2031626646 creator A5022366907 @default.
• W2031626646 creator A5033185488 @default.
• W2031626646 creator A5037644603 @default.
• W2031626646 creator A5089791667 @default.
• W2031626646 date "2011-11-01" @default.
• W2031626646 modified "2023-09-26" @default.
• W2031626646 title "Abstract B92: Differences in gene expression between primary chemotherapy-naive prostate carcinomas and hormone-refractory prostate carcinomas." @default.
• W2031626646 doi "https://doi.org/10.1158/1535-7163.targ-11-b92" @default.
• W2031626646 hasPublicationYear "2011" @default.
• W2031626646 type Work @default.
• W2031626646 sameAs 2031626646 @default.
• W2031626646 citedByCount "1" @default.
• W2031626646 countsByYear W20316266462013 @default.
• W2031626646 crossrefType "journal-article" @default.
• W2031626646 hasAuthorship W2031626646A5022366907 @default.
• W2031626646 hasAuthorship W2031626646A5033185488 @default.
• W2031626646 hasAuthorship W2031626646A5037644603 @default.
• W2031626646 hasAuthorship W2031626646A5089791667 @default.
• W2031626646 hasConcept C104317684 @default.
• W2031626646 hasConcept C121608353 @default.
• W2031626646 hasConcept C126322002 @default.
• W2031626646 hasConcept C143998085 @default.
• W2031626646 hasConcept C150194340 @default.
• W2031626646 hasConcept C162317418 @default.
• W2031626646 hasConcept C2776235491 @default.
• W2031626646 hasConcept C2779013556 @default.
• W2031626646 hasConcept C2780192828 @default.
• W2031626646 hasConcept C2780283643 @default.
• W2031626646 hasConcept C502942594 @default.
• W2031626646 hasConcept C54355233 @default.
• W2031626646 hasConcept C71924100 @default.
• W2031626646 hasConcept C86803240 @default.
• W2031626646 hasConceptScore W2031626646C104317684 @default.
• W2031626646 hasConceptScore W2031626646C121608353 @default.
• W2031626646 hasConceptScore W2031626646C126322002 @default.
• W2031626646 hasConceptScore W2031626646C143998085 @default.
• W2031626646 hasConceptScore W2031626646C150194340 @default.
• W2031626646 hasConceptScore W2031626646C162317418 @default.
• W2031626646 hasConceptScore W2031626646C2776235491 @default.
• W2031626646 hasConceptScore W2031626646C2779013556 @default.
• W2031626646 hasConceptScore W2031626646C2780192828 @default.
• W2031626646 hasConceptScore W2031626646C2780283643 @default.
• W2031626646 hasConceptScore W2031626646C502942594 @default.
• W2031626646 hasConceptScore W2031626646C54355233 @default.
• W2031626646 hasConceptScore W2031626646C71924100 @default.
• W2031626646 hasConceptScore W2031626646C86803240 @default.
• W2031626646 hasIssue "11_Supplement" @default.
• W2031626646 hasLocation W20316266461 @default.
• W2031626646 hasOpenAccess W2031626646 @default.
• W2031626646 hasPrimaryLocation W20316266461 @default.
• W2031626646 hasRelatedWork W1980245127 @default.
• W2031626646 hasRelatedWork W2106003470 @default.
• W2031626646 hasRelatedWork W2133366443 @default.
• W2031626646 hasRelatedWork W2165919621 @default.
• W2031626646 hasRelatedWork W2400504790 @default.
• W2031626646 hasRelatedWork W2429027331 @default.
• W2031626646 hasRelatedWork W2433835599 @default.
• W2031626646 hasRelatedWork W3012091774 @default.
• W2031626646 hasRelatedWork W3080128047 @default.
• W2031626646 hasRelatedWork W4362495310 @default.
• W2031626646 hasVolume "10" @default.
• W2031626646 isParatext "false" @default.
• W2031626646 isRetracted "false" @default.
• W2031626646 magId "2031626646" @default.
• W2031626646 workType "article" @default.